Biotechnology

A new method of grouping colorectal cancer patients using DPE sequencing

[ad_1]

“(…) DPE analysis may have an important role in improving the diagnosis and management of CRC.”

Credit: 2023 Rubio-Mangas et al.

“(…) DPE analysis may have an important role in improving the diagnosis and management of CRC.”

BUFFALO, NY- April 7, 2023 – A new editorial paper was published at Oncoscience (Volume 10) on March 23, 2023 entitled, “A new method of grouping colorectal cancer patients using differential presence of exons (DPE) sequencing..”

Colorectal cancer (CRC) is a heterogeneous disease that occurs in the colon and rectum, parts of the digestive system. CRC is the third leading cause of cancer-related death worldwide. The incidence and mortality of CRC are expected to increase significantly in the future, with more than 2.2 million new cases and 1.1 million deaths expected by 2030.

Metastases are the main cause of death in CRC patients, especially liver metastases. According to previous studies, about 25% of CRC cases are clinically diagnosed with liver metastases at an early stage, and about 50% of CRC patients develop symptoms of liver metastases during the course of the disease. Differential presence of exons (DPE) by next-generation sequencing (NGS) is an innovative method for analyzing complete exome sequences and can be used as a stratification and predictive tool in patients with colorectal cancer (CRC).

In this editorial, researcher David Rubio-Mangas, Mariano Garcia-Arranz, Javier Suela And Damian Garcia Olmo from The Jiménez Díaz Foundation Health Research Institute, Autonomous University of Madrid And Jimenez Diaz Foundation Hospital discussed DPE analysis as a new and promising technique in the field of liquid biopsy which has non-invasive advantages over invasive diagnostic techniques. In addition, this analysis can provide valuable information about the development of CRC and can provide information about response to therapy.

“Use of liquid biopsies in clinical practice can also reduce the cost and time required to stage CRC patients, which can have implications for diagnosis and treatment (12, 13).”

Continue Reading Editorial: https://www.oncoscience.us/article/573/

Correspondence to: David Rubio-Mangas, Damian Garcia-Olmo

E-mail: (email protected), (email protected)

Keywords: whole exome sequencing, NGS, cell-free DNA, DPE, exon differential presence

About Oncoscience:

Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, particularly new topics not currently covered by other journals. This journal has a special mission: Freeing oncologists from publication fees. It’s free for readers and writers.

To learn more about Oncosciencevisit Oncoscience. us and connect with us on social media:

  • Twitter
  • Facebook
  • YouTube
  • LinkedIn

For media inquiries, please contact (email protected).

Oncoscience Journal Office

6666 East Quaker Str., Suite 1D

Orchard Park, New York 14127

Telephone: 1-800-922-0957, option 4

###




[ad_2]

Source link

Related Articles

Back to top button